Cessation of low-dose gonadotropin releasing hormone agonist therapy followed by high-dose gonadotropin stimulation yields a favorable ovarian response in poor responders

This study is a prospective nonrandomized study to determine the effect of a new protocol of controlled ovarian hyperstimulation (COH) using low doses and a half-period of gonadotropin releasing hormone agonist (GnRHa) followed by high doses of gonadotropin in patients who were supposed to be poor r...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of assisted reproduction and genetics 2002, Vol.19 (1), p.1-6
Hauptverfasser: WANG, Pu-Tsui, LEE, Robert Kuo-Kuang, SU, Jin-Tsung, HOU, Jen-Wan, LIN, Ming-Huei, HU, Yu-Ming
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 6
container_issue 1
container_start_page 1
container_title Journal of assisted reproduction and genetics
container_volume 19
creator WANG, Pu-Tsui
LEE, Robert Kuo-Kuang
SU, Jin-Tsung
HOU, Jen-Wan
LIN, Ming-Huei
HU, Yu-Ming
description This study is a prospective nonrandomized study to determine the effect of a new protocol of controlled ovarian hyperstimulation (COH) using low doses and a half-period of gonadotropin releasing hormone agonist (GnRHa) followed by high doses of gonadotropin in patients who were supposed to be poor responders to standard long protocols of GnRHa administration. From Dec 1996 to Nov 1998, 50 patients who were classified as "poor responders" were scheduled for 52 cycles of a modified controlled ovarian hyperstimulation protocol. They were categorized into 3 groups: a group of poor responders to COH in the previous IVF or IUI cycles, a group with elevated Day 3 FSH levels, and a group over the age of 40 years. All patients received GnRH agonist from the midluteal phase of the previous cycle to the onset of menstruation in the next cycle. Then high doses of gonadotropins (HMG/FSH) were given. The patients then had standard courses of in vitro fertilization and embryo transfer (IVF-ET) or transfallopian embryo transfer (TET). Six of the 52 cycles of the modified protocols were cancelled because of poor ovarian response. One premature ovulation was noted before ovum retrieval was performed. In the other 45 cycles, an average of 6.3 mature oocytes were retrieved. The total pregnancy rate and implantation rate were 20.5 and 11.5%, respectively. The low dose and half duration of GnRHa therapy lessened the suppression of the response of the ovaries to COH compared with the regular long protocol of GnRHa down regulation therapy. This resulted in a low cancellation rate (11.8%), a favorable embryo implantation rate (11.5%), and an acceptable clinical pregnancy rate (20.5%).
doi_str_mv 10.1023/A:1014026220880
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3455668</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71509936</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-504d2f56664a45b3b7584ac4aadafda664d4729e0cac6a138861882b5821d0053</originalsourceid><addsrcrecordid>eNptkUur1TAUhYso3oeOnUkQdFbNu6kD4XLwqnDBiY7LbpOe5pJm16Q9cv6Sv9LIPT5xlGTvb629NqmqJ4y-ZJSLV1evGWWScs05NYbeq86ZakTdCEHvlztVpqZSm7PqIudbSmlruHhYnTFmWlFe59W3ncsZVo-R4EgCfq0tZkf2GMHimnDxkSQXHGQf92TCNGN0BErf55Wsk0uwHMmIoUidJf2RTH4__cckr37ewt2ko3fBZgJkhAMm6IMjeIDk4cesvGAs4iJZENOpYF3Kj6oHI4TsHp_Oy-rz9dtPu_f1zcd3H3ZXN_UgqV5rRaXlo9JaS5CqF32jjIRBAlgYLZSylQ1vHR1g0MCEMZoZw3tlOLOUKnFZvbnzXbZ-dnZwcU0QuiX5GdKxQ_Dd353op26Ph05IVcaaYvDiZJDwy-by2s0-Dy4EiA633DVM0bYVuoDP_gFvcUuxLNdxpjWjJVKBnv4Z51eOn39YgOcnAPIAYUwQB59_c0IpYYQS3wGBM7Cd</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216610821</pqid></control><display><type>article</type><title>Cessation of low-dose gonadotropin releasing hormone agonist therapy followed by high-dose gonadotropin stimulation yields a favorable ovarian response in poor responders</title><source>MEDLINE</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>WANG, Pu-Tsui ; LEE, Robert Kuo-Kuang ; SU, Jin-Tsung ; HOU, Jen-Wan ; LIN, Ming-Huei ; HU, Yu-Ming</creator><creatorcontrib>WANG, Pu-Tsui ; LEE, Robert Kuo-Kuang ; SU, Jin-Tsung ; HOU, Jen-Wan ; LIN, Ming-Huei ; HU, Yu-Ming</creatorcontrib><description>This study is a prospective nonrandomized study to determine the effect of a new protocol of controlled ovarian hyperstimulation (COH) using low doses and a half-period of gonadotropin releasing hormone agonist (GnRHa) followed by high doses of gonadotropin in patients who were supposed to be poor responders to standard long protocols of GnRHa administration. From Dec 1996 to Nov 1998, 50 patients who were classified as "poor responders" were scheduled for 52 cycles of a modified controlled ovarian hyperstimulation protocol. They were categorized into 3 groups: a group of poor responders to COH in the previous IVF or IUI cycles, a group with elevated Day 3 FSH levels, and a group over the age of 40 years. All patients received GnRH agonist from the midluteal phase of the previous cycle to the onset of menstruation in the next cycle. Then high doses of gonadotropins (HMG/FSH) were given. The patients then had standard courses of in vitro fertilization and embryo transfer (IVF-ET) or transfallopian embryo transfer (TET). Six of the 52 cycles of the modified protocols were cancelled because of poor ovarian response. One premature ovulation was noted before ovum retrieval was performed. In the other 45 cycles, an average of 6.3 mature oocytes were retrieved. The total pregnancy rate and implantation rate were 20.5 and 11.5%, respectively. The low dose and half duration of GnRHa therapy lessened the suppression of the response of the ovaries to COH compared with the regular long protocol of GnRHa down regulation therapy. This resulted in a low cancellation rate (11.8%), a favorable embryo implantation rate (11.5%), and an acceptable clinical pregnancy rate (20.5%).</description><identifier>ISSN: 1058-0468</identifier><identifier>EISSN: 1573-7330</identifier><identifier>DOI: 10.1023/A:1014026220880</identifier><identifier>PMID: 11893009</identifier><identifier>CODEN: JARGE4</identifier><language>eng</language><publisher>New York, NY: Kluwer/Plenum</publisher><subject>Adult ; Age ; Biological and medical sciences ; Embryos ; Female ; Fertility Agents, Female - administration &amp; dosage ; Fertility Agents, Female - pharmacology ; Fertilization in Vitro ; Follicle Stimulating Hormone - administration &amp; dosage ; Follicle Stimulating Hormone - blood ; Follicle Stimulating Hormone - pharmacology ; Follicles ; Genital system. Reproduction ; Gonadotropin-Releasing Hormone - agonists ; Gonadotropins - pharmacology ; Humans ; In vitro fertilization ; Leuprolide - administration &amp; dosage ; Leuprolide - pharmacology ; Medical sciences ; Menstruation ; Ovaries ; Ovulation Induction ; Patients ; Pharmacology. Drug treatments ; Pregnancy ; Pregnancy Outcome ; Ultrasonic imaging</subject><ispartof>Journal of assisted reproduction and genetics, 2002, Vol.19 (1), p.1-6</ispartof><rights>2002 INIST-CNRS</rights><rights>Copyright Kluwer Academic Publishers Jan 2002</rights><rights>Plenum Publishing Corporation 2002</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-504d2f56664a45b3b7584ac4aadafda664d4729e0cac6a138861882b5821d0053</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3455668/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3455668/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,4022,27921,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13553835$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11893009$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WANG, Pu-Tsui</creatorcontrib><creatorcontrib>LEE, Robert Kuo-Kuang</creatorcontrib><creatorcontrib>SU, Jin-Tsung</creatorcontrib><creatorcontrib>HOU, Jen-Wan</creatorcontrib><creatorcontrib>LIN, Ming-Huei</creatorcontrib><creatorcontrib>HU, Yu-Ming</creatorcontrib><title>Cessation of low-dose gonadotropin releasing hormone agonist therapy followed by high-dose gonadotropin stimulation yields a favorable ovarian response in poor responders</title><title>Journal of assisted reproduction and genetics</title><addtitle>J Assist Reprod Genet</addtitle><description>This study is a prospective nonrandomized study to determine the effect of a new protocol of controlled ovarian hyperstimulation (COH) using low doses and a half-period of gonadotropin releasing hormone agonist (GnRHa) followed by high doses of gonadotropin in patients who were supposed to be poor responders to standard long protocols of GnRHa administration. From Dec 1996 to Nov 1998, 50 patients who were classified as "poor responders" were scheduled for 52 cycles of a modified controlled ovarian hyperstimulation protocol. They were categorized into 3 groups: a group of poor responders to COH in the previous IVF or IUI cycles, a group with elevated Day 3 FSH levels, and a group over the age of 40 years. All patients received GnRH agonist from the midluteal phase of the previous cycle to the onset of menstruation in the next cycle. Then high doses of gonadotropins (HMG/FSH) were given. The patients then had standard courses of in vitro fertilization and embryo transfer (IVF-ET) or transfallopian embryo transfer (TET). Six of the 52 cycles of the modified protocols were cancelled because of poor ovarian response. One premature ovulation was noted before ovum retrieval was performed. In the other 45 cycles, an average of 6.3 mature oocytes were retrieved. The total pregnancy rate and implantation rate were 20.5 and 11.5%, respectively. The low dose and half duration of GnRHa therapy lessened the suppression of the response of the ovaries to COH compared with the regular long protocol of GnRHa down regulation therapy. This resulted in a low cancellation rate (11.8%), a favorable embryo implantation rate (11.5%), and an acceptable clinical pregnancy rate (20.5%).</description><subject>Adult</subject><subject>Age</subject><subject>Biological and medical sciences</subject><subject>Embryos</subject><subject>Female</subject><subject>Fertility Agents, Female - administration &amp; dosage</subject><subject>Fertility Agents, Female - pharmacology</subject><subject>Fertilization in Vitro</subject><subject>Follicle Stimulating Hormone - administration &amp; dosage</subject><subject>Follicle Stimulating Hormone - blood</subject><subject>Follicle Stimulating Hormone - pharmacology</subject><subject>Follicles</subject><subject>Genital system. Reproduction</subject><subject>Gonadotropin-Releasing Hormone - agonists</subject><subject>Gonadotropins - pharmacology</subject><subject>Humans</subject><subject>In vitro fertilization</subject><subject>Leuprolide - administration &amp; dosage</subject><subject>Leuprolide - pharmacology</subject><subject>Medical sciences</subject><subject>Menstruation</subject><subject>Ovaries</subject><subject>Ovulation Induction</subject><subject>Patients</subject><subject>Pharmacology. Drug treatments</subject><subject>Pregnancy</subject><subject>Pregnancy Outcome</subject><subject>Ultrasonic imaging</subject><issn>1058-0468</issn><issn>1573-7330</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkUur1TAUhYso3oeOnUkQdFbNu6kD4XLwqnDBiY7LbpOe5pJm16Q9cv6Sv9LIPT5xlGTvb629NqmqJ4y-ZJSLV1evGWWScs05NYbeq86ZakTdCEHvlztVpqZSm7PqIudbSmlruHhYnTFmWlFe59W3ncsZVo-R4EgCfq0tZkf2GMHimnDxkSQXHGQf92TCNGN0BErf55Wsk0uwHMmIoUidJf2RTH4__cckr37ewt2ko3fBZgJkhAMm6IMjeIDk4cesvGAs4iJZENOpYF3Kj6oHI4TsHp_Oy-rz9dtPu_f1zcd3H3ZXN_UgqV5rRaXlo9JaS5CqF32jjIRBAlgYLZSylQ1vHR1g0MCEMZoZw3tlOLOUKnFZvbnzXbZ-dnZwcU0QuiX5GdKxQ_Dd353op26Ph05IVcaaYvDiZJDwy-by2s0-Dy4EiA633DVM0bYVuoDP_gFvcUuxLNdxpjWjJVKBnv4Z51eOn39YgOcnAPIAYUwQB59_c0IpYYQS3wGBM7Cd</recordid><startdate>2002</startdate><enddate>2002</enddate><creator>WANG, Pu-Tsui</creator><creator>LEE, Robert Kuo-Kuang</creator><creator>SU, Jin-Tsung</creator><creator>HOU, Jen-Wan</creator><creator>LIN, Ming-Huei</creator><creator>HU, Yu-Ming</creator><general>Kluwer/Plenum</general><general>Springer Nature B.V</general><general>Kluwer Academic Publishers-Plenum Publishers</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2002</creationdate><title>Cessation of low-dose gonadotropin releasing hormone agonist therapy followed by high-dose gonadotropin stimulation yields a favorable ovarian response in poor responders</title><author>WANG, Pu-Tsui ; LEE, Robert Kuo-Kuang ; SU, Jin-Tsung ; HOU, Jen-Wan ; LIN, Ming-Huei ; HU, Yu-Ming</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-504d2f56664a45b3b7584ac4aadafda664d4729e0cac6a138861882b5821d0053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Age</topic><topic>Biological and medical sciences</topic><topic>Embryos</topic><topic>Female</topic><topic>Fertility Agents, Female - administration &amp; dosage</topic><topic>Fertility Agents, Female - pharmacology</topic><topic>Fertilization in Vitro</topic><topic>Follicle Stimulating Hormone - administration &amp; dosage</topic><topic>Follicle Stimulating Hormone - blood</topic><topic>Follicle Stimulating Hormone - pharmacology</topic><topic>Follicles</topic><topic>Genital system. Reproduction</topic><topic>Gonadotropin-Releasing Hormone - agonists</topic><topic>Gonadotropins - pharmacology</topic><topic>Humans</topic><topic>In vitro fertilization</topic><topic>Leuprolide - administration &amp; dosage</topic><topic>Leuprolide - pharmacology</topic><topic>Medical sciences</topic><topic>Menstruation</topic><topic>Ovaries</topic><topic>Ovulation Induction</topic><topic>Patients</topic><topic>Pharmacology. Drug treatments</topic><topic>Pregnancy</topic><topic>Pregnancy Outcome</topic><topic>Ultrasonic imaging</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WANG, Pu-Tsui</creatorcontrib><creatorcontrib>LEE, Robert Kuo-Kuang</creatorcontrib><creatorcontrib>SU, Jin-Tsung</creatorcontrib><creatorcontrib>HOU, Jen-Wan</creatorcontrib><creatorcontrib>LIN, Ming-Huei</creatorcontrib><creatorcontrib>HU, Yu-Ming</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of assisted reproduction and genetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WANG, Pu-Tsui</au><au>LEE, Robert Kuo-Kuang</au><au>SU, Jin-Tsung</au><au>HOU, Jen-Wan</au><au>LIN, Ming-Huei</au><au>HU, Yu-Ming</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cessation of low-dose gonadotropin releasing hormone agonist therapy followed by high-dose gonadotropin stimulation yields a favorable ovarian response in poor responders</atitle><jtitle>Journal of assisted reproduction and genetics</jtitle><addtitle>J Assist Reprod Genet</addtitle><date>2002</date><risdate>2002</risdate><volume>19</volume><issue>1</issue><spage>1</spage><epage>6</epage><pages>1-6</pages><issn>1058-0468</issn><eissn>1573-7330</eissn><coden>JARGE4</coden><abstract>This study is a prospective nonrandomized study to determine the effect of a new protocol of controlled ovarian hyperstimulation (COH) using low doses and a half-period of gonadotropin releasing hormone agonist (GnRHa) followed by high doses of gonadotropin in patients who were supposed to be poor responders to standard long protocols of GnRHa administration. From Dec 1996 to Nov 1998, 50 patients who were classified as "poor responders" were scheduled for 52 cycles of a modified controlled ovarian hyperstimulation protocol. They were categorized into 3 groups: a group of poor responders to COH in the previous IVF or IUI cycles, a group with elevated Day 3 FSH levels, and a group over the age of 40 years. All patients received GnRH agonist from the midluteal phase of the previous cycle to the onset of menstruation in the next cycle. Then high doses of gonadotropins (HMG/FSH) were given. The patients then had standard courses of in vitro fertilization and embryo transfer (IVF-ET) or transfallopian embryo transfer (TET). Six of the 52 cycles of the modified protocols were cancelled because of poor ovarian response. One premature ovulation was noted before ovum retrieval was performed. In the other 45 cycles, an average of 6.3 mature oocytes were retrieved. The total pregnancy rate and implantation rate were 20.5 and 11.5%, respectively. The low dose and half duration of GnRHa therapy lessened the suppression of the response of the ovaries to COH compared with the regular long protocol of GnRHa down regulation therapy. This resulted in a low cancellation rate (11.8%), a favorable embryo implantation rate (11.5%), and an acceptable clinical pregnancy rate (20.5%).</abstract><cop>New York, NY</cop><pub>Kluwer/Plenum</pub><pmid>11893009</pmid><doi>10.1023/A:1014026220880</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1058-0468
ispartof Journal of assisted reproduction and genetics, 2002, Vol.19 (1), p.1-6
issn 1058-0468
1573-7330
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3455668
source MEDLINE; PubMed Central; SpringerLink Journals - AutoHoldings
subjects Adult
Age
Biological and medical sciences
Embryos
Female
Fertility Agents, Female - administration & dosage
Fertility Agents, Female - pharmacology
Fertilization in Vitro
Follicle Stimulating Hormone - administration & dosage
Follicle Stimulating Hormone - blood
Follicle Stimulating Hormone - pharmacology
Follicles
Genital system. Reproduction
Gonadotropin-Releasing Hormone - agonists
Gonadotropins - pharmacology
Humans
In vitro fertilization
Leuprolide - administration & dosage
Leuprolide - pharmacology
Medical sciences
Menstruation
Ovaries
Ovulation Induction
Patients
Pharmacology. Drug treatments
Pregnancy
Pregnancy Outcome
Ultrasonic imaging
title Cessation of low-dose gonadotropin releasing hormone agonist therapy followed by high-dose gonadotropin stimulation yields a favorable ovarian response in poor responders
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T12%3A44%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cessation%20of%20low-dose%20gonadotropin%20releasing%20hormone%20agonist%20therapy%20followed%20by%20high-dose%20gonadotropin%20stimulation%20yields%20a%20favorable%20ovarian%20response%20in%20poor%20responders&rft.jtitle=Journal%20of%20assisted%20reproduction%20and%20genetics&rft.au=WANG,%20Pu-Tsui&rft.date=2002&rft.volume=19&rft.issue=1&rft.spage=1&rft.epage=6&rft.pages=1-6&rft.issn=1058-0468&rft.eissn=1573-7330&rft.coden=JARGE4&rft_id=info:doi/10.1023/A:1014026220880&rft_dat=%3Cproquest_pubme%3E71509936%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=216610821&rft_id=info:pmid/11893009&rfr_iscdi=true